Skip to main content
Top
Published in: World Journal of Surgery 5/2018

01-05-2018 | Original Scientific Report

Low Lifetime Risk of Contralateral Breast Cancer in a Middle-Income Asian Country: Evidence to Guide Post-treatment Surveillance

Authors: M. H. See, N. Bhoo-Pathy, S. Jamaris, A. Kiran, D. G. Evans, C. H. Yip, N. A. Taib

Published in: World Journal of Surgery | Issue 5/2018

Login to get access

Abstract

Background

The rate of contralateral risk-reducing mastectomy (CRRM) is increasing in the West with controversial evidence of improved survival in early breast cancer patients. Although uptake of CRRM in Asia appears low, the trends may rise, and there is currently an urgent need to provide evidence for informed decision-making in clinical practice. This study aims to determine the risk of contralateral breast cancer (CBC) and its associated factors in an Asian setting.

Method

A total of 2937 newly diagnosed patients with stage I and stage II breast cancer in University Malaya Medical Centre between Jan 1993 to Dec 2012 were included in the study. Multinomial logistic regression analysis allowing death to compete with CBC as a study outcome was used; patients with unilateral breast cancer who were alive were taken as reference. A stepwise backward regression analysis including age at diagnosis, ethnicity, family history of breast cancer, TNM stage, hormonal receptor status, HER2 status, chemotherapy, radiotherapy, and hormone therapy was conducted.

Results

Fifty women developed CBC, over a median follow-up of 6 years. The 5- and 10-year cumulative risk of contralateral breast cancer was 1.0% (95% CI 0.6–1.4%) and 2.8% (95% CI 2.0–3.6%), respectively. Young age at diagnosis of first cancer, positive family history, and stage I disease were independent predictors of CBC.

Discussion

The current study suggests that the risk of CBC is very low in a Southeast Asian setting. Any recommendations or practice of CRRM should be reviewed with caution and patients must be counseled appropriately.
Literature
1.
go back to reference Allemani C, Weir HK, Carreira H et al (2015) Global surveillance of cancer survival 1995-2009: analysis of individual data for 25,676,887 patients from 279 population-based registries in 67 countries (CONCORD-2). Lancet 385(9972):977–1010CrossRefPubMed Allemani C, Weir HK, Carreira H et al (2015) Global surveillance of cancer survival 1995-2009: analysis of individual data for 25,676,887 patients from 279 population-based registries in 67 countries (CONCORD-2). Lancet 385(9972):977–1010CrossRefPubMed
2.
go back to reference Saadatmand S, Bretveld R, Siesling S et al (2015) Influence of tumour stage at breast cancer detection on survival in modern times: population based study in 173,797 patients. BMJ 351:h4901CrossRefPubMedPubMedCentral Saadatmand S, Bretveld R, Siesling S et al (2015) Influence of tumour stage at breast cancer detection on survival in modern times: population based study in 173,797 patients. BMJ 351:h4901CrossRefPubMedPubMedCentral
3.
go back to reference Early Breast Cancer Trialists’ Collaborative Group (2005) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and15-year survival: an overview of the randomized trials. Lancet 365(9472):1687–1717CrossRef Early Breast Cancer Trialists’ Collaborative Group (2005) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and15-year survival: an overview of the randomized trials. Lancet 365(9472):1687–1717CrossRef
4.
go back to reference Clarke M, Collins R, Darby S et al (2005) Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. Lancet 366(9503):2087–2106CrossRefPubMed Clarke M, Collins R, Darby S et al (2005) Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. Lancet 366(9503):2087–2106CrossRefPubMed
6.
go back to reference Rasmussen CB, Kjær SK, Ejlertsen B et al (2014) Incidence of metachronous contralateral breast cancer in Denmark 1978–2009. Int J Epidemiol 43(6):1855–1864CrossRefPubMed Rasmussen CB, Kjær SK, Ejlertsen B et al (2014) Incidence of metachronous contralateral breast cancer in Denmark 1978–2009. Int J Epidemiol 43(6):1855–1864CrossRefPubMed
7.
go back to reference Chen Y, Thompson W, Semenciw R et al (1999) Epidemiology of contralateral breast cancer. Cancer Epidemiol Biomarkers Prev 8(10):855–861PubMed Chen Y, Thompson W, Semenciw R et al (1999) Epidemiology of contralateral breast cancer. Cancer Epidemiol Biomarkers Prev 8(10):855–861PubMed
8.
go back to reference Graeser MK, Engel C et al (2009) Contralateral breast cancer risk in BRCA1 and BRCA2 mutation carriers. J Clin Oncol 27(35):5887CrossRefPubMed Graeser MK, Engel C et al (2009) Contralateral breast cancer risk in BRCA1 and BRCA2 mutation carriers. J Clin Oncol 27(35):5887CrossRefPubMed
9.
go back to reference Fayanju OM, Stoll CR, Fowler S, Colditz GA, Margenthaler JA (2014) Contralateral prophylactic mastectomy after unilateral breast cancer: a systematic review and meta-analysis. Ann Surg 260(6):1000–1010CrossRefPubMedPubMedCentral Fayanju OM, Stoll CR, Fowler S, Colditz GA, Margenthaler JA (2014) Contralateral prophylactic mastectomy after unilateral breast cancer: a systematic review and meta-analysis. Ann Surg 260(6):1000–1010CrossRefPubMedPubMedCentral
11.
go back to reference Kurian AW, Lichtensztajn DY, Keegan TH et al (2014) Use of and mortality after bilateral mastectomy compared with other surgical treatments for breast cancer in California, 1998-2011. JAMA 312:902–914CrossRefPubMedPubMedCentral Kurian AW, Lichtensztajn DY, Keegan TH et al (2014) Use of and mortality after bilateral mastectomy compared with other surgical treatments for breast cancer in California, 1998-2011. JAMA 312:902–914CrossRefPubMedPubMedCentral
12.
go back to reference Tuttle TM, Habermann EB, Grund EH et al (2007) Increasing use of contralateral prophylactic mastectomy for breast cancer patients: a trend toward more aggressive surgical treatment. J Clin Oncol 25(33):5203–5209CrossRefPubMed Tuttle TM, Habermann EB, Grund EH et al (2007) Increasing use of contralateral prophylactic mastectomy for breast cancer patients: a trend toward more aggressive surgical treatment. J Clin Oncol 25(33):5203–5209CrossRefPubMed
13.
go back to reference Sim Y, Tan VK, Ho GH et al (2014) Contralateral prophylactic mastectomy in an Asian population: a single institution review. Breast 23(1):56–62CrossRefPubMed Sim Y, Tan VK, Ho GH et al (2014) Contralateral prophylactic mastectomy in an Asian population: a single institution review. Breast 23(1):56–62CrossRefPubMed
14.
go back to reference Pathy NB, Yip CH, Taib NA et al (2011) Breast cancer in a multi-ethnic Asian setting: results from the Singapore–Malaysia hospital-based breast cancer registry. Breast 20(2):S75–S80CrossRefPubMed Pathy NB, Yip CH, Taib NA et al (2011) Breast cancer in a multi-ethnic Asian setting: results from the Singapore–Malaysia hospital-based breast cancer registry. Breast 20(2):S75–S80CrossRefPubMed
15.
go back to reference Gao X, Fisher SG, Emami B (2003) Risk of second primary cancer in the contralateral breast in women treated for early-stage breast cancer: a population-based study. Int J Radiat Oncol Biol Phys 56(4):1038–1045CrossRefPubMed Gao X, Fisher SG, Emami B (2003) Risk of second primary cancer in the contralateral breast in women treated for early-stage breast cancer: a population-based study. Int J Radiat Oncol Biol Phys 56(4):1038–1045CrossRefPubMed
16.
go back to reference Li CI, Malone KE, Weiss NS et al (2001) Tamoxifen therapy for primary breast cancer and risk of contralateral breast cancer. J Natl Cancer Inst 93:1008–1013CrossRefPubMed Li CI, Malone KE, Weiss NS et al (2001) Tamoxifen therapy for primary breast cancer and risk of contralateral breast cancer. J Natl Cancer Inst 93:1008–1013CrossRefPubMed
17.
go back to reference Schaapveld M, Visser O, Louwman WJ et al (2008) The impact of adjuvant therapy on contralateral breast cancer risk and the prognostic signifi-cance of contralateral breast cancer: a population based study in the Netherlands. Breast Cancer Res Treat 110(1):189–197CrossRefPubMed Schaapveld M, Visser O, Louwman WJ et al (2008) The impact of adjuvant therapy on contralateral breast cancer risk and the prognostic signifi-cance of contralateral breast cancer: a population based study in the Netherlands. Breast Cancer Res Treat 110(1):189–197CrossRefPubMed
18.
go back to reference Nichols HB, Berrington de Gonzalez A, Lacey JV et al (2011) Declining incidence of contralateral breast cancer in the United States from 1975 to 2006. J Clin Oncol 29(12):1564–1569CrossRefPubMedPubMedCentral Nichols HB, Berrington de Gonzalez A, Lacey JV et al (2011) Declining incidence of contralateral breast cancer in the United States from 1975 to 2006. J Clin Oncol 29(12):1564–1569CrossRefPubMedPubMedCentral
19.
go back to reference Aihara T, Tanaka S, Sagara Y et al (2014) Incidence of contralateral breast cancer in Japanese patients with unilateral minimum-risk primary breast cancer, and the benefits of endocrine therapy and radiotherapy. Breast Cancer 21(3):284–291CrossRefPubMed Aihara T, Tanaka S, Sagara Y et al (2014) Incidence of contralateral breast cancer in Japanese patients with unilateral minimum-risk primary breast cancer, and the benefits of endocrine therapy and radiotherapy. Breast Cancer 21(3):284–291CrossRefPubMed
20.
go back to reference Healey EA, Cook EF, Orav EJ et al (1993) Contralateral breast cancer: clinical characteristics and impact on prognosis. J Clin Oncol 11(8):1545–1552CrossRefPubMed Healey EA, Cook EF, Orav EJ et al (1993) Contralateral breast cancer: clinical characteristics and impact on prognosis. J Clin Oncol 11(8):1545–1552CrossRefPubMed
21.
go back to reference Kollias J, Ellis IO, Elston CW et al (1999) Clinical and histological predictors of contralateral breast cancer. Eur J Surg Oncol 25(6):584–589CrossRefPubMed Kollias J, Ellis IO, Elston CW et al (1999) Clinical and histological predictors of contralateral breast cancer. Eur J Surg Oncol 25(6):584–589CrossRefPubMed
22.
go back to reference Robbins GF, Berg JW (1964) Bilateral primary breast cancer: a prospective clinicopathological study. Cancer 17:1501–1527CrossRefPubMed Robbins GF, Berg JW (1964) Bilateral primary breast cancer: a prospective clinicopathological study. Cancer 17:1501–1527CrossRefPubMed
23.
go back to reference Marmor S, Portschy PR, Burke EE et al (2017) Prognostic factors for metachronous contralateral breast cancer: implications for management of the contralateral breast. Breast J 23(3):299–306CrossRefPubMed Marmor S, Portschy PR, Burke EE et al (2017) Prognostic factors for metachronous contralateral breast cancer: implications for management of the contralateral breast. Breast J 23(3):299–306CrossRefPubMed
24.
go back to reference Prater J, Valeri F, Korol D et al (2016) Incidence of metachronous contralateral breast cancer in the Canton of Zurich: a population-based study of the cancer registry. J Cancer Res Clin Oncol 142(2):365–371CrossRefPubMed Prater J, Valeri F, Korol D et al (2016) Incidence of metachronous contralateral breast cancer in the Canton of Zurich: a population-based study of the cancer registry. J Cancer Res Clin Oncol 142(2):365–371CrossRefPubMed
25.
go back to reference Yadav BS, Sharma SC, Patel FD et al (2008) Second primary in the contralateral breast after treatment of breast cancer. Radiother Oncol 86(2):171–176CrossRefPubMed Yadav BS, Sharma SC, Patel FD et al (2008) Second primary in the contralateral breast after treatment of breast cancer. Radiother Oncol 86(2):171–176CrossRefPubMed
26.
go back to reference Lizarraga IM, Sugg SL, Weigel RJ et al (2013) Review of risk factors for the development of contralateral breast cancer. Am J Surg 206(5):704–708CrossRefPubMed Lizarraga IM, Sugg SL, Weigel RJ et al (2013) Review of risk factors for the development of contralateral breast cancer. Am J Surg 206(5):704–708CrossRefPubMed
27.
go back to reference Bernstein JL, Lapinski RH, Thakore SS et al (2003) The descriptive epidemiology of second primary breast cancer. Epidemiology 14:552–558CrossRefPubMed Bernstein JL, Lapinski RH, Thakore SS et al (2003) The descriptive epidemiology of second primary breast cancer. Epidemiology 14:552–558CrossRefPubMed
28.
go back to reference Chen Y, Thompson W, Semenciw R et al (1999) Epidemiology of Contralateral breast Cancer. Cancer Epidemiol Biomark Prev 8:855–861 Chen Y, Thompson W, Semenciw R et al (1999) Epidemiology of Contralateral breast Cancer. Cancer Epidemiol Biomark Prev 8:855–861
29.
go back to reference Narod SA, Kharazmi E, Fallah M et al (2016) The risk of contralateral breast cancer in daughters of women with and without breast cancer. Clin Genet 89(3):332–335CrossRefPubMed Narod SA, Kharazmi E, Fallah M et al (2016) The risk of contralateral breast cancer in daughters of women with and without breast cancer. Clin Genet 89(3):332–335CrossRefPubMed
30.
go back to reference King TA, Sakr R, Patil S et al (2011) Clinical management factors contribute to the decision for contralateral prophylactic mastectomy. J Clin Oncol 29(16):2158–2164CrossRefPubMed King TA, Sakr R, Patil S et al (2011) Clinical management factors contribute to the decision for contralateral prophylactic mastectomy. J Clin Oncol 29(16):2158–2164CrossRefPubMed
31.
go back to reference Boughey JC, Hoskin TL, Degnim AC et al (2010) Contralateral prophylactic mastectomy is associated with a survival advantage in high-risk women with a personal history of breast cancer. Ann Surg Oncol 17(10):2702–2709CrossRefPubMedPubMedCentral Boughey JC, Hoskin TL, Degnim AC et al (2010) Contralateral prophylactic mastectomy is associated with a survival advantage in high-risk women with a personal history of breast cancer. Ann Surg Oncol 17(10):2702–2709CrossRefPubMedPubMedCentral
32.
go back to reference Portschy PR, Kuntz KM, Tuttle TM (2014) Survival outcomes after contralateral prophylactic mastectomy: a decision analysis. J Natl Cancer Inst 106(8):16CrossRef Portschy PR, Kuntz KM, Tuttle TM (2014) Survival outcomes after contralateral prophylactic mastectomy: a decision analysis. J Natl Cancer Inst 106(8):16CrossRef
34.
go back to reference Boughey JC, Attai DJ, Chen SL et al (2016) Contralateral Prophylactic Mastectomy (CPM) Consensus Statement from the American Society of Breast Surgeons: data on CPM Outcomes and Risks. Ann Surg Oncol 23(10):3100–3105CrossRefPubMedPubMedCentral Boughey JC, Attai DJ, Chen SL et al (2016) Contralateral Prophylactic Mastectomy (CPM) Consensus Statement from the American Society of Breast Surgeons: data on CPM Outcomes and Risks. Ann Surg Oncol 23(10):3100–3105CrossRefPubMedPubMedCentral
35.
go back to reference Molina-Montes E, Pérez-Nevot B, Pollán M, Sánchez-Cantalejo E et al (2014) Cumulative risk of second primary contralateral breast cancer in BRCA1/BRCA2 mutation carriers with a first breast cancer: a systematic review and meta-analysis. Breast 23(6):721–742CrossRefPubMed Molina-Montes E, Pérez-Nevot B, Pollán M, Sánchez-Cantalejo E et al (2014) Cumulative risk of second primary contralateral breast cancer in BRCA1/BRCA2 mutation carriers with a first breast cancer: a systematic review and meta-analysis. Breast 23(6):721–742CrossRefPubMed
36.
go back to reference Tesson S, Richards I, Porter D et al (2017) Women’s preferences for contralateral prophylactic mastectomy following unilateral breast cancer: What risk-reduction makes it worthwhile? Breast 31:233–240CrossRefPubMed Tesson S, Richards I, Porter D et al (2017) Women’s preferences for contralateral prophylactic mastectomy following unilateral breast cancer: What risk-reduction makes it worthwhile? Breast 31:233–240CrossRefPubMed
Metadata
Title
Low Lifetime Risk of Contralateral Breast Cancer in a Middle-Income Asian Country: Evidence to Guide Post-treatment Surveillance
Authors
M. H. See
N. Bhoo-Pathy
S. Jamaris
A. Kiran
D. G. Evans
C. H. Yip
N. A. Taib
Publication date
01-05-2018
Publisher
Springer International Publishing
Published in
World Journal of Surgery / Issue 5/2018
Print ISSN: 0364-2313
Electronic ISSN: 1432-2323
DOI
https://doi.org/10.1007/s00268-017-4319-6

Other articles of this Issue 5/2018

World Journal of Surgery 5/2018 Go to the issue